Mirum Pharmaceuticals, Inc. MIRM
Sales up 54.7%, free cash flow up to $54.9M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (34, from the latest 10-K and 10-Q)
- EPS (ttm)
- -14.47
- Sales (ttm)
- 670.8M
- Net income (ttm)
- -903.9M
- Sales growth
- +54.7%
- EPS growth
- -
- Sales Q/Q
- +39.6%
- Free cash flow
- -273.9M
- Gross margin
- -
- Oper. margin
- -133.6%
- Net margin
- -134.8%
- FCF margin
- -40.8%
- ROE
- n/m
- ROA
- -88.0%
- R&D / sales
- 35.7%
- Dividend
- -
- Debt/Eq
- n/m
- Curr. ratio
- 2.07
- Cash
- 243.2M
- Op. cash flow (ttm)
- -271.3M
- EBITDA
- 2.1M
- EBITDA margin
- 0.4%
- Quick ratio
- 1.98
- Interest cover
- -1.54
- FCF after stock pay
- -16.6M
- Oper. margin low 5y
- -906.1%
- Stock pay / sales
- 13.7%
- Shares out.
- 65.3M
- Shares Y/Y
- +5.6%
- Book / share
- -0.83
- Cash / share
- 3.73
- Sales / share
- 10.28
- Asset turnover
- 0.65
- Days sales out.
- 86
- Sales 3Y CAGR
- +89.1%
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2020 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
MIRM against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals, Inc. | $670.8M | +54.7% | - | -134.8% | - | -40.8% | - |
| RARE Ultragenyx Pharmaceutical Inc. | $730.0M | +20.2% | - | -71.8% | - | -60.5% | - |
| TMDX TransMedics Group, Inc. | $727.6M | +37.1% | 58.6% | 19.9% | 26.2% | 6.1% | - |
| GKOS GLAUKOS Corp | $690.3M | +32.3% | 64.8% | -24.6% | -23.7% | 5.2% | - |
| TARS Tarsus Pharmaceuticals, Inc. | $682.2M | +147% | - | -102.9% | - | 4.8% | 0.70 |
| UFPT UFP Technologies Inc | $649.5M | +19.5% | 28.9% | 11.8% | 15.8% | - | 0.20 |
Where the $521.3M of revenue came from
by product, year to Dec 31, 2025
- Livmarli $360.0M · 69%
- Bile Acid Medicines $161.3M · 31%
From the segment tables in the 10-K XBRL.
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2021 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin below the peer median-134.8% vs 6.8%
-
A profit in 0 of 6 years
Balance sheet
-
Interest covered less than 5 timesOperating income is -1.5× interest expense
-
Current assets cover current liabilitiesCurrent ratio 2.07
Cash and shareholders
-
Free cash flow positive in 2 of 6 years$54.9M last year
-
Share count up over 4 years+65.6%
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Contracted revenue and deferred revenue
Backlog (remaining performance obligations) and cash received in advance, by balance sheet date · XBRL
Both are balance-sheet-date values from the 10-K and 10-Qs. Backlog is what is under contract, not a forecast: contracts can be cancelled or change in size, and a company counts them in its own way. Hover a number for its XBRL line; click it to open the filing.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
MIRM's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 7. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Revenue by product or service
year to Dec 31, 2025| Revenue | Share | vs year before | |
|---|---|---|---|
| Livmarli | 360.0M | 69.1% | +68.8% |
| Bile Acid Medicines | 161.3M | 30.9% | +31.0% |
| License and other revenue | 0 | 0.0% | -100% |
10-K 0001759425-26-000013, segment and revenue notes (XBRL).
Income statement
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 19.1M | 77.1M | 186.4M | 336.9M | 521.3M |
| R&D | 43.0M | 81.6M | 131.4M | 106.8M | 102.6M | 140.6M | 186.2M |
| SG&A | 11.8M | 22.7M | 59.2M | 89.1M | 145.9M | 202.2M | 257.0M |
| Operating income | -54.7M | -104.3M | -173.4M | -131.2M | -109.2M | -87.6M | -22.1M |
| Interest expense | - | - | 0 | 16.0M | 15.1M | 14.3M | 14.4M |
| Pretax income | -52.5M | -103.3M | -84.0M | -142.1M | -162.4M | -86.9M | -21.4M |
| Income tax | 21K | 6K | 37K | -6.4M | 991K | 1.0M | 1.9M |
| Net income | -52.6M | -103.3M | -84.0M | -135.7M | -163.4M | -87.9M | -23.4M |
| EPS (diluted) | -4.58 | -4.09 | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 |
| Diluted shares | - | - | 30.3M | 34.0M | 40.9M | 47.5M | 50.2M |
| Depreciation & amortization | 139K | 305K | 595K | 3.2M | 10.8M | 23.6M | 24.2M |
| EBITDA | -54.6M | -104.0M | -172.8M | -128.0M | -98.3M | -64.0M | 2.1M |
| Operating margin | - | - | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Net margin | - | - | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
| Revenue growth | - | - | - | +303% | +142% | +80.8% | +54.7% |
Balance sheet
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Cash | 12.0M | 142.1M | 31.3M | 28.0M | 286.3M | 222.5M | 296.7M |
| Short-term investments | 104.7M | 89.7M | 125.2M | 123.7M | 0 | 57.8M | 86.6M |
| Receivables | - | 0 | 3.3M | 24.0M | 68.0M | 78.3M | 123.3M |
| Inventory | - | 0 | 1.5M | 5.6M | 22.3M | 22.4M | 24.9M |
| Current assets | 119.4M | 236.3M | 166.6M | 190.2M | 387.5M | 392.8M | 549.7M |
| Property & equipment | 1.4M | 1.3M | 981K | 914K | 706K | 1.1M | 1.9M |
| Other intangible assets | - | 0 | 18.7M | 59.0M | 252.9M | 249.8M | 260.9M |
| Total assets | 146.7M | 240.9M | 294.7M | 352.9M | 646.6M | 670.8M | 842.8M |
| Accounts payable | 3.4M | 3.2M | 9.2M | 8.7M | 7.4M | 14.6M | 9.6M |
| Current liabilities | 13.1M | 18.5M | 42.6M | 64.7M | 87.1M | 126.6M | 205.8M |
| Total liabilities | 16.4M | 68.8M | 174.4M | 210.9M | 398.0M | 445.1M | 528.1M |
| Shareholders' equity | 130.3M | 172.1M | 120.2M | 142.0M | 248.7M | 225.6M | 314.7M |
| Retained earnings | -69.9M | -173.2M | -257.2M | -392.8M | -556.2M | -644.2M | -667.5M |
Cash flow
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -39.4M | -89.1M | -132.8M | -120.1M | -70.9M | 10.3M | 55.8M |
| Capital spending | 281K | 225K | 24K | 278K | 109K | 993K | 954K |
| Free cash flow | -39.6M | -89.3M | -132.8M | -120.4M | -71.1M | 9.3M | 54.9M |
| Stock-based pay (added back) | 6.1M | 12.6M | 23.1M | 27.0M | 35.0M | 48.4M | 71.4M |
| Free cash flow after stock pay | -45.7M | -101.9M | -155.9M | -147.4M | -106.1M | -39.1M | -16.6M |
| Acquisitions | - | - | 0 | 0 | 212.8M | 0 | 0 |
| Investing cash flow | -127.8M | 37.9M | 48.5M | 7.7M | -107.2M | -90.1M | -24.0M |
| Financing cash flow | 127.2M | 181.3M | 73.5M | 109.1M | 336.6M | 17.7M | 40.1M |
Stock-based pay and leases
From EDGAR| FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 6.1M | 12.6M | 23.1M | 27.0M | 35.0M | 48.4M | 71.4M |
| Stock-based pay / revenue | - | - | 120.6% | 35.0% | 18.8% | 14.4% | 13.7% |
| Operating lease cash paid | 170K | 576K | 864K | 911K | 1.1M | 1.3M | 2.6M |
| Right-of-use assets | 2.4M | 1.9M | 1.6M | 1.4M | 1.3M | 8.7M | 8.7M |
| Operating lease liabilities | 3.6M | 3.3M | 2.6M | 2.2M | 1.7M | 9.7M | 9.7M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/MIRM/export.csv") into a cell.